A preliminary study on Lp-PLA2 and its relationship with LDL-C and hs-CRP in southern China

doi:10.3969/j.issn.1673-8640.2021.012.006

Abstract

Abstract:

Objective To investigate the distribution of lipoprotein-associated phospholipase A2（Lp-PLA2） levels in southern China,and to evaluate the relationship between Lp-PLA2 and low-density lipoprotein cholesterol（LDL-C）,high-sensitivity C-reactive protein（hs-CRP）. Methods A total of 2 318 serum samples were collected from 8 Grade 3 Class A hospitals in southern China. Lp-PLA2,blood lipids [total cholesterol（TC）,triglyceride（TG） and high-density lipoprotein cholesterol（HDL-C）] and hs-CRP levels were determined. All the subjects were classified according to sex and ages（<50 years old,50-59 years old,60-69 years old,70-79 years old and ≥80 years old）. Pearson or Spearman correlation analysis was performed to evaluate the correlations between the items. Results The Lp-PLA2 level of 2 318 healthy subjects in southern China was（145.84±43.96） ng/mL,and the upper limit of reference interval was 217.93 ng/mL. The level of serum Lp-PLA2 in females was lower than that in maless（P<0.05）. The level of serum Lp-PLA2 in <50 years old group was lower than those in 50-59,60-69 and 70-79 years old groups（P<0.05）,and there was no statistical significance compared with that in ≥80 years old group（P>0.05）. There was no statistical significance in serum Lp-PLA2 levels among 50-59,60-69 and 70-79 years old groups（P>0.05）. Among the 8 hospitals,the level of Lp-PLA2 in the Union Hospital Affiliated to Fujian Medical University was the lowest,while the level of Lp-PLA2 in Hainan Provincial People's Hospital was the highest,and there was statistical significance compared with the other hospitals（P<0.05）. Lp-PLA2 was positively correlated with LDL-C（r=0.163,P<0.05）,and there was no correlation with TC,TG,HDL-C and hs-CRP（r values were -0.028,0.000,0.001 and 0.088,P>0.05,respectively）. Conclusions The reference interval of Lp-PLA2 in healthy subjects in southern China has been established preliminarily.

Key words: Lipoprotein-associated phospholipase A2, Low-density lipoprotein cholesterol, High-sensitivity C-reactive protein

CLC Number:

Q556

ZHAO Jingjing, ZHANG Peng, ZHOU Yong, CAO Yingping, HUANG Zhihu, FU Shengmiao, WANG Yuming, HONG Guolin, SHEN Jun, ZHENG Lei. A preliminary study on Lp-PLA2 and its relationship with LDL-C and hs-CRP in southern China[J]. Laboratory Medicine, 2021, 36(12): 1222-1228.

Figures/Tables 5

References 31

[1]	中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9):833-854.
[2]	YAMAURA S, SAKASEGAWA S I, KOGUMA E, et al. Novel enzymatic method for assaying Lp-PLA₂ in serum[J]. Clin Chim Acta, 2018, 481:184-188. DOI URL
[3]	WINKLER K, WINKELMANN B R, SCHARNAGL H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors:the Ludwigshafen Risk and Cardiovascular Health Study[J]. Circulation, 2005, 111(8):980-987. DOI URL
[4]	SORRIENTO D, IACCARINO G. Inflammation and cardiovascular diseases:the most recent findings[J]. Int J Mol Sci, 2019, 20(16):3879. DOI URL
[5]	WOLF D, LEY K. Immunity and inflammation in atherosclerosis[J]. Circ Res, 2019, 124(2):315-327. DOI URL
[6]	PACKARD C J, O'REILLY D S,CASLAKE M J,et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group[J]. N Engl J Med, 2000, 343(16):1148-1155. DOI URL
[7]	ELKIND M S, TAI W, COATES K, et al. High-sensitivity C-reactive protein,lipoprotein-associated phospholipase A2,and outcome after ischemic stroke[J]. Arch Intern Med, 2006, 166(19):2073-2080. DOI URL
[8]	COLLEY K J, WOLFERT R L, COBBLE M E. Lipoprotein associated phospholipase A(2):role in atherosclerosis and utility as a biomarker for cardiovascular risk[J]. EPMA J, 2011, 2(1):27-38. DOI URL
[9]	CAI A, LI G, CHEN J, et al. Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases:a cross-sectional study of Chinese population[J]. BMC Cardiovasc Disord, 2015, 15:14. DOI URL
[10]	GREENLAND P, ALPERT J S, BELLER G A, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2010, 56(25):e50-e103. DOI URL
[11]	PERK J, DE BACKER G, GOHLKE H, et al. European Guidelines on cardiovascular disease prevention in clinical practice(version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice(constituted by representatives of nine societies and by invited experts)[J]. Eur Heart J, 2012, 33(13):1635-1701. DOI URL
[12]	Clinical and Laboratory Standards Institute. Defining,establishing,and verifying reference intervals in the clinical laboratory[S]. C28-A3,CLSI, 2008.
[13]	中华人民共和国国家卫生健康委员会. WS/T 404.4—2018 临床常用生化检验项目参考区间. 第4部分:血清总胆红素、直接胆红素[S]. 2018.
[14]	尚红, 王毓三, 申子瑜. 全国临床检验操作规程[M]. 4版. 北京: 人民卫生出版社, 2015.
[15]	中华人民共和国卫生部. WS/T 402—2012 临床实验室检验项目参考区间的制定[S]. 2012.
[16]	LEE K K, FORTMANN S P, VARADY A, et al. Racial variation in lipoprotein-associated phospholipase A₂ in older adults[J]. BMC Cardiovasc Disord, 2011, 11:38. DOI URL
[17]	蔺亚晖, 龚美亮, 张鹏, 等. 中国50岁以上表观健康人群多中心外周血脂蛋白相关磷脂酶A2质量浓度参考区间研究[J]. 中华检验医学杂志, 2021, 44(1):32-38.
[18]	丰睿捷, 胡晓晨, 赵莉芳, 等. 表观健康人群血清脂蛋白相关磷脂酶A2参考区间的建立[J]. 检验医学, 2017, 32(6):495-499.
[19]	廖琳, 胡敏, 陈若虹, 等. 长沙地区体检健康成年人血清脂蛋白相关磷脂酶A2活性参考区间的建立[J]. 临床检验杂志, 2018, 36(6):422-425.
[20]	毋小玉, 崔发财, 郑培明, 等. 采用连续监测法建立郑州地区健康成年人血清脂蛋白相关磷脂酶A2活性参考区间[J]. 实验与检验医学, 2021, 39(1):202-205.
[21]	中国老年学学会心脑血管病专业委员会, 中国医师协会检验医师分会心脑血管病专家委员会. 脂蛋白相关磷脂酶A2临床应用专家建议[J]. 中华心血管病杂志, 2015, 43(10):843-847.
[22]	WASSERTHEIL-SMOLLER S, KOOPERBERG C, MCGINN A P, et al. Lipoprotein-associated phospholipase A2,hormone use,and the risk of ischemic stroke in postmenopausal women[J]. Hypertension, 2008, 51(4):1115-1122. DOI URL
[23]	JIANG W W, NIU J D, QI M J, et al. Diagnostic value of combined detection of different indicators for type 2 diabetes mellitus combined with atherosclerotic disease[J]. Zhonghua Yi Xue Za Zhi, 2021, 101(31):2448-2453.
[24]	SOFOGIANNI A, ALKAGIET S, TZIOMALOS K. Lipoprotein-associated phospholipase A2 and coronary Heart Disease[J]. Curr Pharm Des, 2018, 24(3):291-296. DOI URL
[25]	RAVNSKOV U, DE LORGERIL M, DIAMOND D M, et al. LDL-C does not cause cardiovascular disease:a comprehensive review of the current literature[J]. Expert Rev Clin Pharmacol, 2018, 11(10):959-970. DOI URL
[26]	ALBERT M A, GLYNN R J, WOLFERT R L, et al. The effect of statin therapy on lipoprotein associated phospholipase A2 levels[J]. Atherosclerosis, 2005, 182(1):193-198. DOI URL
[27]	RIDKER P M, MACFADYEN J G, WOLFERT R L, et al. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy:an analysis from the JUPITER trial[J]. Clin Chem, 2012, 58(5):877-886. DOI URL
[28]	BLAKE G J, DADA N, FOX J C, et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women[J]. J Am Coll Cardiol, 2001, 38(5):1302-1306. DOI URL
[29]	EISAF M, TSELEPIS A D. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis[J]. Biochem Pharmacol, 2003, 66(11):2069-2073. DOI URL
[30]	ROGER V L, GO A S, LLOYD-JONES D M, et al. Heart disease and stroke statistics-2011 update:a report from the American Heart Association[J]. Circulation, 2011, 123(4):e18-e209.
[31]	YANG S, HUANG S, DANIELS L B, et al. NT-proBNP,race and endothelial function in the Multi-Ethnic Study of Atherosclerosis[J]. Heart, 2019, 105(20):1590-1596. DOI URL

性别	例数	Lp-PLA2	参考区间上限
男性	1 205	152.13±44.83	225.65
女性	1 113	139.03±41.98	207.88
合计	2 318	145.84±43.96	217.93

性别	例数	Lp-PLA2	参考区间上限
男性	1 205	152.13±44.83	225.65
女性	1 113	139.03±41.98	207.88
合计	2 318	145.84±43.96	217.93

组别	例数	Lp-PLA2	95%可信区间
<50岁组	167	133.00±42.56	126.50~139.51
50~59岁组	1 076	147.07±44.05^*	144.43~149.70
60~69岁组	636	147.23±43.13^*	143.87~150.59
70~79岁组	326	147.65±45.15^*	142.73~152.57
≥80岁组	113	140.10±43.56	131.98~148.22

组别	例数	Lp-PLA2	95%可信区间
<50岁组	167	133.00±42.56	126.50~139.51
50~59岁组	1 076	147.07±44.05^*	144.43~149.70
60~69岁组	636	147.23±43.13^*	143.87~150.59
70~79岁组	326	147.65±45.15^*	142.73~152.57
≥80岁组	113	140.10±43.56	131.98~148.22

组别	例数	Lp-PLA2	95%可信区间
男性
<50岁组	78	141.16±42.48^#△	131.58~150.73
50~59岁组	508	155.17±45.29^*□	151.22~159.12
60~69岁组	355	153.71±43.01^*□	149.22~158.20
70~79岁组	199	149.52±46.92	142.96~156.08
≥80岁组	65	140.95±44.26^#△	129.98~151.92
女性
<50岁组	89	125.86±41.56^#△▲	117.10~134.61
50~59岁组	568	139.82±41.64^*	136.39~143.25
60~69岁组	281	139.04±41.94^*	134.12~143.97
70~79岁组	127	144.73±42.24^*	137.31~152.15
≥80岁组	48	138.95±43.04	126.45~151.45